CN105339357A - 适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物 - Google Patents

适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物 Download PDF

Info

Publication number
CN105339357A
CN105339357A CN201480026453.XA CN201480026453A CN105339357A CN 105339357 A CN105339357 A CN 105339357A CN 201480026453 A CN201480026453 A CN 201480026453A CN 105339357 A CN105339357 A CN 105339357A
Authority
CN
China
Prior art keywords
ethyl
trans
base
pyrimidine
cis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480026453.XA
Other languages
English (en)
Chinese (zh)
Inventor
A.豪普特
J.丁格斯
L.昂格
K.维克
R.范瓦特朔特
K.德雷舍尔
A.L.雷洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
AbbVie Inc
Original Assignee
AbbVie Deutschland GmbH and Co KG
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Deutschland GmbH and Co KG, AbbVie Inc filed Critical AbbVie Deutschland GmbH and Co KG
Publication of CN105339357A publication Critical patent/CN105339357A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480026453.XA 2013-03-15 2014-03-14 适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物 Pending CN105339357A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361786869P 2013-03-15 2013-03-15
US61/786869 2013-03-15
US201361918524P 2013-12-19 2013-12-19
US61/918524 2013-12-19
PCT/EP2014/055062 WO2014140246A1 (en) 2013-03-15 2014-03-14 Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor

Publications (1)

Publication Number Publication Date
CN105339357A true CN105339357A (zh) 2016-02-17

Family

ID=50280387

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480026453.XA Pending CN105339357A (zh) 2013-03-15 2014-03-14 适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物

Country Status (11)

Country Link
US (1) US9388148B2 (https=)
EP (1) EP2970146B1 (https=)
JP (1) JP2016514117A (https=)
CN (1) CN105339357A (https=)
AU (1) AU2014230215A1 (https=)
BR (1) BR112015021471A2 (https=)
CA (1) CA2902656A1 (https=)
MX (1) MX2015012184A (https=)
TW (1) TW201514154A (https=)
UY (1) UY35420A (https=)
WO (1) WO2014140246A1 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020156312A1 (zh) * 2019-01-30 2020-08-06 江苏豪森药业集团有限公司 一种多环类衍生物调节剂、其制备方法和应用
CN112239433A (zh) * 2019-07-17 2021-01-19 北京盈科瑞创新药物研究有限公司 一种环己烷衍生物、制备方法及其应用
WO2021083246A1 (zh) * 2019-10-29 2021-05-06 上海翰森生物医药科技有限公司 四元环类衍生物调节剂、其制备方法和应用
CN113754580A (zh) * 2020-06-05 2021-12-07 上海中泽医药科技有限公司 一种吡啶吗啉类化合物、其制备方法及其应用
WO2022228447A1 (zh) * 2021-04-28 2022-11-03 上海翰森生物医药科技有限公司 含哌嗪多环类衍生物的盐及晶型及其制备方法和应用
RU2833027C1 (ru) * 2019-10-29 2025-01-13 Шанхай Хэнсох Биомедикал Ко., Лтд. Модификатор производного четырехчленного кольца, способ его получения и его применение

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
AR095264A1 (es) * 2013-03-15 2015-09-30 Abbvie Deutschland Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
UY35420A (es) 2013-03-15 2014-10-31 Abbvie Inc Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
EP3744721B1 (en) 2018-01-26 2025-07-02 Shionogi & Co., Ltd. Condensed ring compounds having dopamine d3 receptor antagonistic effect
JP7250405B2 (ja) 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンd3受容体拮抗作用を有する環式化合物
TWI873212B (zh) * 2019-10-29 2025-02-21 大陸商上海翰森生物醫藥科技有限公司 四員環類衍生物調節劑、其製備方法和應用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066885A1 (de) * 2004-12-21 2006-06-29 Abbott Gmbh & Co. Kg Substituierte n-heterocyclische verbindungen und ihre verwendung als dopamin d3 rezeptorliganden
US20090143398A1 (en) * 2007-12-03 2009-06-04 Gizella Bartane Szalai Pyrimidinyl-piperazines useful as d3/d2 receptor ligands
CN101511805A (zh) * 2006-06-22 2009-08-19 生物计划公司 作为多巴胺d3受体配体的新型羰基化(氮杂)环己烷类化合物
CN102947310A (zh) * 2010-06-21 2013-02-27 霍夫曼-拉罗奇有限公司 作为5-ht2a和d3受体的双重调节剂的稠合吡啶化合物
CN102958936A (zh) * 2010-07-06 2013-03-06 霍夫曼-拉罗奇有限公司 稠合的吡啶化合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10311065A1 (de) 2003-03-13 2004-09-23 Abbott Gmbh & Co. Kg Pyrimidin-2-on-Verbindungen und ihre therapeutische Verwendung
TW200510395A (en) 2003-06-05 2005-03-16 Abbott Gmbh & Co Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
DE102004027359A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
ES2340941T3 (es) 2004-08-09 2010-06-11 ABBOTT GMBH & CO. KG Compuestos de 4-piperazinil-pirimidina adecuados para tretar trastornos que responden a modulacion del receptor d 3 de dopamina.
HUP0500170A3 (en) 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
WO2008065500A2 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Heteroaryl amides as type i glycine transport inhibitors
WO2009003868A2 (en) 2007-07-02 2009-01-08 F. Hoffmann-La Roche Ag 2 -imidazolines having a good affinity to the trace amine associated receptors (taars)
PA8802101A1 (es) 2007-11-02 2009-08-26 Abbott Gmbh & Co Kg Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3
JP5367824B2 (ja) * 2008-09-22 2013-12-11 エフ.ホフマン−ラ ロシュ アーゲー ピペラジンd3及び5−ht2a受容体調節薬
AU2009296047A1 (en) 2008-09-23 2010-04-01 F. Hoffmann-La Roche Ag Pyridinylpiperazin derivatives useful as modulators of dopamine D3 receptors
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
UY35420A (es) 2013-03-15 2014-10-31 Abbvie Inc Compuestos de acilaminocicloalquilo apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006066885A1 (de) * 2004-12-21 2006-06-29 Abbott Gmbh & Co. Kg Substituierte n-heterocyclische verbindungen und ihre verwendung als dopamin d3 rezeptorliganden
CN101511805A (zh) * 2006-06-22 2009-08-19 生物计划公司 作为多巴胺d3受体配体的新型羰基化(氮杂)环己烷类化合物
US20090143398A1 (en) * 2007-12-03 2009-06-04 Gizella Bartane Szalai Pyrimidinyl-piperazines useful as d3/d2 receptor ligands
CN102947310A (zh) * 2010-06-21 2013-02-27 霍夫曼-拉罗奇有限公司 作为5-ht2a和d3受体的双重调节剂的稠合吡啶化合物
CN102958936A (zh) * 2010-07-06 2013-03-06 霍夫曼-拉罗奇有限公司 稠合的吡啶化合物

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111770754A (zh) * 2019-01-30 2020-10-13 江苏豪森药业集团有限公司 一种多环类衍生物调节剂、其制备方法和应用
WO2020156312A1 (zh) * 2019-01-30 2020-08-06 江苏豪森药业集团有限公司 一种多环类衍生物调节剂、其制备方法和应用
CN111770754B (zh) * 2019-01-30 2023-09-19 江苏豪森药业集团有限公司 一种多环类衍生物调节剂、其制备方法和应用
TWI850321B (zh) * 2019-01-30 2024-08-01 大陸商江蘇豪森藥業集團有限公司 一種多環類衍生物調節劑、其製備方法和應用
CN112239433A (zh) * 2019-07-17 2021-01-19 北京盈科瑞创新药物研究有限公司 一种环己烷衍生物、制备方法及其应用
CN112239433B (zh) * 2019-07-17 2024-05-14 北京盈科瑞创新药物研究有限公司 一种环己烷衍生物、制备方法及其应用
RU2833027C1 (ru) * 2019-10-29 2025-01-13 Шанхай Хэнсох Биомедикал Ко., Лтд. Модификатор производного четырехчленного кольца, способ его получения и его применение
WO2021083246A1 (zh) * 2019-10-29 2021-05-06 上海翰森生物医药科技有限公司 四元环类衍生物调节剂、其制备方法和应用
CN113056454A (zh) * 2019-10-29 2021-06-29 上海翰森生物医药科技有限公司 四元环类衍生物调节剂、其制备方法和应用
CN113754580A (zh) * 2020-06-05 2021-12-07 上海中泽医药科技有限公司 一种吡啶吗啉类化合物、其制备方法及其应用
CN113754580B (zh) * 2020-06-05 2023-04-25 上海中泽医药科技有限公司 一种吡啶吗啉类化合物、其制备方法及其应用
US12410136B2 (en) 2020-06-05 2025-09-09 Shanghai Zhongze Therapeutics, Co. Ltd. Pyridinyl morpholine compound, preparation method therefor, and application thereof
WO2022228447A1 (zh) * 2021-04-28 2022-11-03 上海翰森生物医药科技有限公司 含哌嗪多环类衍生物的盐及晶型及其制备方法和应用
CN117242058A (zh) * 2021-04-28 2023-12-15 上海翰森生物医药科技有限公司 含哌嗪多环类衍生物的盐及晶型及其制备方法和应用

Also Published As

Publication number Publication date
JP2016514117A (ja) 2016-05-19
EP2970146A1 (en) 2016-01-20
AU2014230215A1 (en) 2015-09-03
TW201514154A (zh) 2015-04-16
WO2014140246A1 (en) 2014-09-18
CA2902656A1 (en) 2014-09-18
US20140303176A1 (en) 2014-10-09
EP2970146B1 (en) 2017-11-01
BR112015021471A2 (pt) 2017-07-18
UY35420A (es) 2014-10-31
MX2015012184A (es) 2016-05-16
US9388148B2 (en) 2016-07-12

Similar Documents

Publication Publication Date Title
CN105339357A (zh) 适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物
CN104854103B (zh) 适用于治疗对多巴胺d3受体的调节有反应的病症的酰基氨基环烷基化合物
WO2021127459A1 (en) Gpr139 receptor modulators
RU2478633C2 (ru) Производные 1,2,4-триазин-3,5-диона для лечения нарушений, реагирующих на модулирование рецептора допамина d3
US9388141B2 (en) Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
CN101918384A (zh) 适合治疗响应5-羟色胺5-ht6受体调节的疾病的苯磺酰苯胺化合物
EP2203426B1 (en) Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
CN116323583A (zh) 用于对亨廷顿蛋白成像的杂联芳基化合物和显像剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160217

RJ01 Rejection of invention patent application after publication